查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010934

甲状腺癌治疗市场：按癌症类型、治疗方法、药物类型、给药途径和最终用户划分－2026年至2032年全球市场预测

Thyroid Cancer Drugs Market by Cancer Type, Treatment Modality, Drug Type, Mode Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，甲状腺癌治疗市场价值将达到 9.9483 亿美元，到 2026 年将成长至 10.9292 亿美元，到 2032 年将达到 21.1444 亿美元，复合年增长率为 11.37%。

主要市场统计数据
基准年 2025 9.9483亿美元
预计年份：2026年 1,092,920,000 美元
预测年份 2032 211444亿美元
复合年增长率 (%) 11.37%

为策略决策者提供关于重塑甲状腺癌治疗格局的临床、商业性和营运驱动因素的全面概述。

甲状腺癌的治疗模式正在迅速发展，无论从科学层面或临床层面来看，新的治疗方法都在重塑临床路径和相关人员的预期。本执行摘要旨在为读者概述当前治疗方法、产品类型和终端用户趋势，并阐述其对製药公司、保险公司、医疗服务提供者和临床研究人员的战略意义。

先进的诊断技术、监管柔软性和门诊护理趋势如何汇聚起来，改变甲状腺癌治疗的模式以及相关人员的角色？

过去几年，甲状腺癌的治疗模式已从相对静态的治疗模式转变为以动态创新和治疗方法多样化为特征的模式。精准诊断和分子分层提高了标靶治疗的重要性，使临床医生能够根据肿瘤突变谱和抗药性模式製定个人化的治疗方法。因此，多激酶抑制剂和选择性标靶药物的临床应用范围不断扩大，而免疫疗法联合治疗在治疗困难组织学亚型方面也得到了越来越多的探索。

评估 2025 年关税对供应链调整的影响及其对甲状腺癌治疗的采购、临床运作和取得策略的下游影响。

2025年关税和贸易政策调整的实施，为全球医药供应链引入了新的变数，并带来了可衡量的营运和策略影响。对于甲状腺癌治疗而言，由于其通常依赖复杂活性成分的采购和跨境生产，进口关税的提高进一步凸显了供应链透明度和双重采购策略的重要性。累积而言，采购惯例已被重新评估，重点也再次转向优化製造地，以降低关税变化带来的风险。

将癌症组织学类型、治疗方法、药物类别、给药途径和最终用户趋势与商业化和临床策略要求联繫起来的详细細項分析。

基于细分市场的洞察揭示了有助于产品开发、市场进入规划和临床定位的细微模式。本分析基于癌症类型，涵盖了未分化型甲状腺癌 (ATC)、滤泡型甲状腺癌 (FTC)、哈特尔细胞癌、髓样甲状腺癌 (MTC) 和乳头状甲状腺癌 (PTC)，重点阐述了它们各自独特的自然病程和治疗需求，这些差异决定了临床优先事项和循证策略的不同。按治疗方法划分，本研究检验了化疗、免疫疗法、放射性碘疗法、手术、靶向多激酶疗法和甲状腺刺激素(TSH) 抑制疗法，展示了每种治疗方法的独特价值提案如何影响治疗方法选择、报销途径和跨学科合作。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和进入趋势影响招募和打入市场策略。

区域情报重点在于影响全球市场治疗策略的区域性监管、临床和准入趋势。在美洲，法规环境强调快速审批途径和可靠的真实世界证据收集，从而支持加速采用生物标誌物主导治疗方法，并为基于疗效和管理式准入合约创造机会。该地区的临床实践正日益整合多学科诊疗模式和先进的基因组检测，推动精准医疗和口服治疗方法的早期应用。

决定甲状腺肿瘤学成功与否的竞争和企业策略，包括产品线优先排序、诊断领域的合作以及以结果主导的商业化能力。

企业层面的发展趋势对甲状腺肿瘤领域的竞争定位和治疗方法差异化至关重要。领先的製药和生技公司正透过内部药物研发、策略联盟和有针对性的收购等多种方式推进其研发管线，尤其关注针对侵袭性或难治性组织学类型甲状腺肿瘤的未满足医疗需求的药物。纵观整体竞争格局，成功的公司往往能够将强大的临床项目与清晰的伴随诊断策略以及上市后核准实践计划相结合。

为製药公司和支付方提供切实可行的建议，以协调诊断、供应弹性、患者支持和灵活合同，从而实现持续的治疗成功。

行业领导者应采取一系列有针对性的行动，将科学进步转化为永续的患者获益。应优先将分子诊断儘早整合到临床开发计划中，并透过使研究终点与支付方关注的结果一致，简化报销谈判流程。同时，应投资于供应链冗余和近岸生产方案，以减轻关税和贸易相关干扰，并确保及时获得关键治疗方法。

结合专家访谈、第二手资料审查和检验技术的稳健混合方法研究框架，确保了可操作和可靠的见解。

本分析的研究方法结合了结构化的原始研究和全面的二手研究，并辅以严格的检验。原始资料来自对临床专业人员、相关专科的资深临床医生、供应链负责人和支付方的深入访谈，旨在了解第一线人员对治疗模式、获取障碍和实际情况的观点。二手研究则整合了同侪审查的文献、监管文件、临床试验註册资讯和公开的产品标籤，以阐明治疗机制和证据成熟度。

将临床、商业性和营运方面的挑战进行策略整合，相关人员必须解决这些挑战，才能将创新与改善患者预后连结起来。

总之，甲状腺癌治疗领域正朝着更个人化、主导的模式转变，诊断、治疗和医疗服务紧密结合。精准医学的进步和新的监管途径正在加速临床应用，但同时也需要完善的商业化和运作策略，以确保患者获得治疗并维持临床效益。此外，关税和区域政策差异等外部因素带来的供应链风险，凸显了适应性规划和合作伙伴关係的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按癌症类型分類的甲状腺癌治疗市场

  • 未分化型甲状腺癌（ATC）
  • 滤泡性甲状腺癌（FTC）
  • 哈斯勒细胞癌
  • 甲状腺髓样癌（MTC）
  • 乳突状甲状腺癌（PTC）

第九章：甲状腺癌治疗市场（依治疗方法划分）

  • 化疗
  • 免疫疗法
  • 放射性碘疗法
  • 外科手术
  • 标靶多激酶疗法
  • 甲状腺刺激素（TSH）抑制疗法

第十章：甲状腺癌治疗药物市场

  • 化疗药物
  • 荷尔蒙疗法药物
  • 免疫疗法药物
  • 分子标靶疗法

第十一章：按给药途径分類的甲状腺癌治疗药物市场

  • 注射药物
    • 预填充式注射器
    • 管瓶
  • 口服
    • 胶囊
    • 药片

第十二章 甲状腺癌治疗市场：依最终用户划分

  • 居家医疗
  • 医院
  • 肿瘤诊所
  • 研究机构

第十三章 甲状腺癌治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 甲状腺癌治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 甲状腺癌治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国甲状腺癌治疗市场

第十七章：中国甲状腺癌治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Loxo Oncology, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market was valued at USD 994.83 million in 2025 and is projected to grow to USD 1,092.92 million in 2026, with a CAGR of 11.37%, reaching USD 2,114.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 994.83 million
Estimated Year [2026] USD 1,092.92 million
Forecast Year [2032] USD 2,114.44 million
CAGR (%) 11.37%

Comprehensive overview of clinical, commercial, and operational drivers reshaping the thyroid cancer treatment landscape for strategic decision-makers

The therapeutic landscape for thyroid cancer is undergoing rapid scientific and clinical evolution, with novel modalities reshaping clinical pathways and stakeholder expectations. This executive summary sets out to orient readers to the current state of play across treatment approaches, product classes, and end-user dynamics, and to outline strategic implications for manufacturers, payers, providers, and clinical researchers.

Beginning with a concise framing of disease heterogeneity and clinical urgency, the narrative moves through the contemporary therapeutic mix and the forces driving change, including regulatory approvals, real-world evidence generation, and shifts in care delivery. Emphasis is given to the interplay between targeted molecular therapies, immuno-oncology agents, and established modalities such as surgery and radioiodine, underscoring how multidisciplinary treatment decisions now rely on increasingly precise biomarker and genomic information.

Importantly, the introduction also highlights commercial and operational considerations that accompany scientific progress - from supply chain resilience to patient access pathways - setting the context for the deeper analytical sections that follow. This establishes the foundation for informed strategic planning and investment prioritization in thyroid cancer therapeutics.

How precision diagnostics, regulatory flexibility, and outpatient care trends are converging to transform thyroid cancer treatment paradigms and stakeholder roles

Across the past several years, the thyroid cancer landscape has shifted from a relatively static treatment paradigm to one characterized by dynamic innovation and therapeutic diversification. Precision diagnostics and molecular stratification have elevated the importance of targeted therapies, enabling clinicians to tailor treatment regimens to tumor mutation profiles and resistance patterns. Consequently, the clinical role of multikinase inhibitors and selective targeted agents has expanded, while immunotherapy combinations are increasingly explored for difficult-to-treat histologies.

Parallel to scientific advances, regulatory frameworks have adapted to accommodate accelerated approval pathways, conditional authorizations, and label expansions driven by biomarker-defined cohorts. Health systems are responding to these changes by investing in multidisciplinary tumor boards and genomic testing infrastructure, which in turn influence referral patterns and treatment sequencing. Additionally, the maturation of oral onco-pharmaceuticals and outpatient-centered regimens is shifting care away from inpatient settings, with implications for administration, adherence, and long-term patient management.

In short, transformative shifts are being driven by a convergence of precision medicine, regulatory flexibility, and care-delivery realignment, creating both opportunities for innovative therapeutics and operational challenges for manufacturers and providers alike.

Assessment of 2025 tariff-driven supply chain recalibrations and their downstream effects on procurement, clinical operations, and access strategies for thyroid cancer therapies

The imposition of tariffs and trade policy adjustments in 2025 introduced new variables into the global pharmaceutical supply chain with measurable operational and strategic consequences. For thyroid cancer therapeutics, which often rely on complex active pharmaceutical ingredient sourcing and cross-border manufacturing, increased import duties have amplified the importance of supply chain mapping and dual-sourcing strategies. The cumulative effect has been a re-evaluation of procurement practices and a renewed focus on manufacturing footprint optimization to mitigate exposure to tariff volatility.

Moreover, tariffs have reinforced the need for greater transparency in costing and pricing strategy. Organizations are increasingly factoring potential trade-related cost pressures into procurement contracts and long-term supplier partnerships. Clinical trial logistics have also been impacted, with sponsors adjusting trial site selection and investigational medicinal product distribution plans to reduce customs-related delays and ensure continuity of patient access to investigational therapies.

Finally, in response to these headwinds, stakeholders have accelerated investments in near-shore manufacturing, supply resiliency programs, and collaborative contracting models. These adaptations aim to preserve therapeutic availability and protect patient access while maintaining predictable delivery timelines in a changing tariff environment.

Deep segmentation analysis linking cancer histology, treatment modality, drug class, administration route, and end-user dynamics to commercialization and clinical strategy imperatives

Segmentation-based insights reveal nuanced patterns that inform product development, market access planning, and clinical positioning. Based on Cancer Type, the analysis covers Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hurthle Cell Carcinoma, Medullary Thyroid Cancer (MTC), and Papillary Thyroid Cancer (PTC), highlighting the distinct natural histories and therapeutic needs that dictate differential clinical priorities and evidence generation strategies. Based on Treatment Modality, the study examines Chemotherapy, Immunotherapy, Radioiodine Therapy, Surgery, Targeted Multikinase Therapy, and Thyroid Stimulating Hormone (TSH) Suppression Therapy, demonstrating how modality-specific value propositions influence adoption, reimbursement pathways, and cross-specialty coordination.

Based on Drug Type, distinctions among Chemotherapy Agents, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs underscore the varying development timelines, safety profiles, and companion diagnostic dependencies that sponsors must navigate. Based on Mode Of Administration, injectable and oral forms are evaluated, with the Injectable further disaggregated into Pre-Filled Syringes and Vials and the Oral subdivided into Capsules and Tablets; this distinction influences manufacturing complexity, patient adherence patterns, and distribution logistics. Based on End User, the report addresses Homecare Settings, Hospitals, Oncology Clinics, and Research Organizations, each representing unique purchasing behaviors, clinical workflows, and post-market evidence opportunities.

Taken together, these segmentation lenses demonstrate that effective commercialization strategies require an integrated approach that aligns clinical development with administration logistics and end-user dynamics, while also prioritizing evidence generation that resonates with the decision criteria of diverse stakeholder groups.

Region-specific clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption and market entry strategies

Regional intelligence highlights distinct regulatory, clinical, and access dynamics that shape therapeutic strategy across global markets. In the Americas, the regulatory environment emphasizes expedited review pathways and robust real-world evidence collection, which supports accelerated uptake for biomarker-driven therapies and creates opportunities for outcome-based contracting and managed entry agreements. Clinical practice in this region tends to integrate multidisciplinary care delivery models and advanced genomic testing, driving early adoption of precision therapeutics and oral treatment regimens.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and reimbursement systems necessitates tailored market entry tactics that account for country-level HTA processes, variability in diagnostic infrastructure, and differences in hospital procurement. Stakeholders should prioritize evidence packages that align with regional HTA endpoints and invest in local clinician engagement to navigate heterogeneous payer environments. Additionally, capacity constraints in parts of the region can influence access to advanced modalities such as radioiodine therapy and immuno-oncology combinations.

In Asia-Pacific, diverse regulatory timelines and accelerating investment in oncology research create a complex but opportunity-rich landscape. Many jurisdictions in this region are expanding molecular testing and decentralizing cancer care, which in turn supports broader population access to targeted and oral therapies. Strategic partnerships with local manufacturers, attention to pricing and reimbursement nuances, and investment in regional real-world evidence generation will be critical to achieving sustainable access and uptake across Asia-Pacific markets.

Competitive and corporate strategies that define success in thyroid oncology including pipeline prioritization, diagnostics partnerships, and outcome-driven commercialization capabilities

Company-level dynamics are central to competitive positioning and therapeutic differentiation in thyroid oncology. Leading pharmaceutical and biotechnology companies are advancing pipelines through a combination of internal discovery, strategic collaborations, and targeted acquisitions, with particular emphasis on agents that address unmet needs in aggressive or refractory histologies. Across the competitive set, successful companies are those that couple robust clinical programs with clear companion diagnostic strategies and post-authorization evidence generation plans.

Commercially, organizations that invest in integrated launch capabilities - combining payer engagement, clinician education, and patient support services - are better positioned to accelerate uptake of new therapies. Operational excellence in supply chain management and manufacturing scale-up is equally critical to avoid launch disruptions and to support global demand. Partnerships between biopharma firms and diagnostic providers are increasingly common, reflecting the need to bundle testing and treatment pathways to optimize clinical outcomes and payer value assessments.

Finally, companies demonstrating agility in pricing models and contracting arrangements, including risk-sharing agreements and value-based frameworks, are more likely to secure access in environments where payers demand demonstrable outcomes. These company-level approaches collectively define who will convert clinical innovation into sustained therapeutic impact.

Practical and high-impact recommendations for manufacturers and payers to align diagnostics, supply resilience, patient support, and flexible contracting for sustained therapeutic success

Industry leaders should adopt a set of targeted actions to translate scientific progress into sustainable patient impact. Prioritize integration of molecular diagnostics into clinical development plans early, aligning study endpoints with payer-relevant outcomes to streamline reimbursement discussions. Simultaneously, invest in supply chain redundancies and near-shore manufacturing options to mitigate tariff and trade-related disruptions while preserving timely access to critical therapies.

Moreover, foster collaborations across the ecosystem by forming partnerships with diagnostic companies, academic centers, and regional distributors to expedite adoption and to build localized evidence. Enhance patient support programs to address adherence and administration barriers, particularly as oral regimens and homecare delivery models become more prevalent. From a commercial perspective, develop flexible contracting strategies that allow for outcome-based elements and adaptive pricing aligned with real-world performance.

Finally, embed agile decision-making processes into R&D and commercial operations so that learnings from early real-world deployments can rapidly inform label expansions, combination therapy studies, and lifecycle management. These actions will help organizations convert innovation into measurable clinical and commercial success.

Robust mixed-methods research framework combining expert interviews, secondary evidence review, and validation techniques to ensure actionable and credible insights

The research approach underpinning this analysis combines structured primary research with comprehensive secondary synthesis and rigorous validation. Primary inputs were derived from in-depth interviews with clinical experts, senior clinicians across relevant specialties, supply chain leaders, and payers to capture first-hand perspectives on treatment patterns, access hurdles, and operational realities. Secondary synthesis incorporated peer-reviewed literature, regulatory documentation, clinical trial registries, and publicly available product labels to contextualize therapeutic mechanisms and evidence maturations.

Data validation involved triangulating stakeholder interviews with clinical guideline trends and regulatory actions to ensure consistency and to identify divergences between trial settings and real-world practice. The methodology also employed scenario analysis to stress-test assumptions around supply disruptions, policy shifts, and treatment pathway changes. Where applicable, patient pathway mapping was used to surface friction points in diagnosis, treatment initiation, and long-term follow-up.

Collectively, these methodological elements ensure that the insights presented are grounded in real-world clinical practice and operational feasibility, providing a robust foundation for strategic decision-making by industry and clinical stakeholders.

Strategic synthesis of clinical, commercial, and operational imperatives that stakeholders must address to convert innovation into improved patient outcomes

In conclusion, the thyroid cancer therapeutic arena is transitioning toward a more personalized, evidence-driven paradigm in which diagnostics, therapeutics, and care delivery are tightly interdependent. Precision medicine advances and new regulatory pathways are enabling faster clinical translation, but they also demand sophisticated commercialization and operational strategies to ensure patient access and to sustain clinical benefit. Moreover, external dynamics such as tariff-induced supply chain risks and regional policy heterogeneity underscore the importance of adaptive planning and collaborative partnerships.

For stakeholders seeking to lead in this environment, success will hinge on aligning clinical development with payer-relevant evidence, building resilient manufacturing and distribution networks, and investing in end-user engagement across hospitals, clinics, and homecare settings. By doing so, manufacturers, providers, and policymakers can collectively improve outcomes for diverse thyroid cancer patient populations while navigating the complex commercial and operational landscape.

This summary provides a strategic vantage point for executives and clinicians to prioritize initiatives that will have the greatest impact on patient care and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Drugs Market, by Cancer Type

  • 8.1. Anaplastic Thyroid Cancer (ATC)
  • 8.2. Follicular Thyroid Cancer (FTC)
  • 8.3. Hurthle Cell Carcinoma
  • 8.4. Medullary Thyroid Cancer (MTC)
  • 8.5. Papillary Thyroid Cancer (PTC)

9. Thyroid Cancer Drugs Market, by Treatment Modality

  • 9.1. Chemotherapy
  • 9.2. Immunotherapy
  • 9.3. Radioiodine Therapy
  • 9.4. Surgery
  • 9.5. Targeted Multikinase Therapy
  • 9.6. Thyroid Stimulating Hormone (TSH) Suppression Therapy

10. Thyroid Cancer Drugs Market, by Drug Type

  • 10.1. Chemotherapy Agents
  • 10.2. Hormone Therapy Drugs
  • 10.3. Immunotherapy Drugs
  • 10.4. Targeted Therapy Drugs

11. Thyroid Cancer Drugs Market, by Mode Of Administration

  • 11.1. Injectable
    • 11.1.1. Pre-Filled Syringes
    • 11.1.2. Vials
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Tablets

12. Thyroid Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Oncology Clinics
  • 12.4. Research Organizations

13. Thyroid Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Thyroid Cancer Drugs Market

17. China Thyroid Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Blueprint Medicines Corporation
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cellectar Biosciences, Inc.
  • 18.12. Eisai Co., Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Exelixis, Inc.
  • 18.15. Genentech, Inc
  • 18.16. Ipsen SA
  • 18.17. Janssen Pharmaceuticals, Inc.
  • 18.18. Loxo Oncology, Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Pfizer Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)